[ad_1]
A successful COVID-19 vaccine could represent a record revenue opportunity for pharmaceutical companies, with a market value of at least $ 10 billion in annual sales, according to analysts.
Die these
The analysts of Morgan Stanley is Swiss credit estimates that people will need the vaccine every year, like a flu shot, at an estimated cost of $ 20 per dose, reports the Financial Times. Matthew Harrison, an analyst at Morgan Stanley, said COVID-19 will not go away and people will need to be vaccinated every year. The size of the market could be as high as $ 10 billion in developed countries alone, even assuming conservatively that only those who get the flu vaccine will receive the COVID-19 vaccine. Credit Suisse analyst Evan Seigerman estimates that the market could be even bigger and worth $ 10 billion in the United States alone.
Should Investors Sell Now? Or is Johnson worth joining, Johnson?
The parties
Also AstraZeneca plc (NASDAQ: AZN) e Johnson & Johnson (NYSE: JNJ) could make money from the vaccine once their promise to administer the vaccine on a cost basis until the pandemic ends, FT noted. The president of Moderna Inc. (NASDAQ: MRNA) Stephen Hoge had said that people at risk would receive booster vaccinations for a while, and while the chance was less than the flu, it was not trivial. Moderna is expected to submit data from the COVID-19 vaccine study to the US regulator in November. The company is developing a vaccine against respiratory syncytial virus and influenza, both of which could be combined with a COVID-19 vaccine. FT notes that pharmaceutical companies have received billions in government funding in the past eight months and could benefit from public money. In July, the former FDA commissioner said the COVID-19 vaccine should have been priced similar to a flu shot, which would have given the company enough margin and some profit to put back into the process. production for future ones Vaccines could be invested. In October, a report claimed that AstraZeneca could benefit from the vaccine starting in July 2021, while another report claimed that the mRNA vaccine was manufactured by Pfizer Inc. (NYSE: PFE) could generate sales of $ 3.5 billion in 2021.
Buy, Hold, or Sell: Your Johnson, Johnson analysis is out of date 05.11. provides the answer:
How will Johnson develop, Johnson now? Is your money safe in this stock? The answers to these questions and why action is needed now can be found in Johnson’s latest stock analysis, Johnson.
Johnson, Johnson: Buy or Sell? Read more here …
Johnson, Johnson Forum
516 investors will receive news and analysis on Johnson, Johnson by email
Source link
